日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial

接受 Rucaparib 维持治疗的 BRCA+ 或 PALB2+ 胰腺癌患者的长期疗效:一项非随机临床试验的二次分析

Reiss, Kim A; Xia, Mingyi; Akamandisa, Mwangala; D'Andrea, Kurt; Wubbenhorst, Brad; Lord, Christopher J; Pettitt, Stephen J; Tutt, Andrew N J; Brown, Timothy J; O'Hara, Mark H; Schneider, Charles; Teitelbaum, Ursina; Hannan, Zain; Hood, Ryan; Tondon, Rashmi; Vonderheide, Robert H; Domchek, Susan M; Nathanson, Katherine L

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

肿瘤特异性 HORMAD1 表达扰乱有丝分裂停滞,并导致对有丝分裂激酶抑制剂的敏感性。

Walker Callum, Kollarovic Gabriel, Weekes Daniel, Trendell Jennifer, Hoffmann Ricarda M, Martin Alexia, Ferro Riccardo, Navarro-Llinas Blanca, Hitchen Luke, Pardo Calvo Mercedes, Balan Nicolae, Kemp Harriet, Carroll Alexandra, Davidson Kathryn, Nath Sarmi, D'Uonno Nadja, Lu Ruifang, Starling Chris, Otten Marieke, Iakobachvili Nino, Marcozzi Chiara, Rahman Ilhan, Quist Jelmar, Yu Lu, Krastev Dragomir B, Amodeo Valeria, Roxanis Ioannis, Grigoriadis Anita, Bayliss Richard, Choudhary Jyoti, Haider Syed, Pines Jonathon, Pettitt Stephen J, Lord Christopher J, Tutt Andrew N J

Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells

更正:APOBEC3B 表达升高驱动 p53 缺陷细胞中类似 kataegic 的突变特征和复制应激相关的治疗脆弱性

Nikkilä, Jenni; Kumar, Rahul; Campbell, James; Brandsma, Inger; Pemberton, Helen N; Wallberg, Fredrik; Nagy, Kinga; Scheer, Ildikó; Vertessy, Beata G; Serebrenik, Artur A; Monni, Valentina; Harris, Reuben S; Pettitt, Stephen J; Ashworth, Alan; Lord, Christopher J

The transcriptomic architecture of common cancers reflects synthetic lethal interactions

常见癌症的转录组结构反映了合成致死相互作用

Haider, Syed; Brough, Rachel; Madera, Santiago; Iacovacci, Jacopo; Gulati, Aditi; Wicks, Andrew; Alexander, John; Pettitt, Stephen J; Tutt, Andrew N J; Lord, Christopher J

Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion

作者更正:Palbociclib 和 dsRNA 传感器协同作用,通过内质网应激和免疫逃逸调节增强抗癌作用。

Roulstone, Victoria; Kyula-Currie, Joan; Wright, James; Patin, Emmanuel C; Dean, Isaac; Yu, Lu; Barreiro-Alonso, Aida; Melake, Miriam; Choudhary, Jyoti; Elliott, Richard; Lord, Christopher J; Mansfield, David; Matthews, Nik; Chauhan, Ritika; Jennings, Victoria; Chan Wah Hak, Charleen; Baldock, Holly; Butera, Francesca; Appleton, Elizabeth; Nenclares, Pablo; Pedersen, Malin; Foo, Shane; Wongariyapak, Amarin; Rullan, Antonio; Tenev, Tencho; Meier, Pascal; Vile, Richard; Pandha, Hardev; Melcher, Alan; McLaughlin, Martin; Harrington, Kevin J

Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.

通过姑息性放射治疗和 ATR 抑制来控制肿瘤和激活免疫,PATRIOT C 部分:一项 Ib 期试验

Dillon Magnus T, Patin Emmanuel C, Mohammed Kabir, Guevara Jeane, Smith Simon A, Dean Emma, Soliman Heba, Nenclares Pablo, Ryugenji Motoko, Northcote Davina, Shah Neel, Grove Lorna, Lord Christopher J, Pettit Stephen, Tall Matt, Swales Karen E, Banerji Udai, Melcher Alan A, Saunders Mark, Forster Martin D, Harrington Kevin J

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

PARP 抑制剂 talazoparib 与呼肠孤病毒协同作用,可在小鼠模型中诱导癌细胞死亡和肿瘤控制

Kyula-Currie Joan, Roulstone Victoria, Wright James, Butera Francesca, Legrand Arnaud, Elliott Richard, McLaughlin Martin, Bozhanova Galabina, Krastev Dragomir, Pettitt Stephen, Tenev Tencho, Dillon Magnus, Foo Shane, Patin Emmanuel C, Jennings Victoria, Chan Wah Hak Charleen, Appleton Elizabeth, Wongariyapak Amarin, Pedersen Malin, Rullan Antonio, Choudhary Jyoti, Bakal Chris, Meier Pascal, Lord Christopher J, Melcher Alan, Harrington Kevin J

Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets

蛋白质基因组学发现RB1缺陷型表型在癌症中具有预测疾病预后、治疗反应和治疗靶点的作用

Iacovacci, Jacopo; Brough, Rachel; Moughari, Fatemeh Ahmadi; Alexander, John; Kemp, Harriet; Tutt, Andrew N J; Natrajan, Rachael; Lord, Christopher J; Haider, Syed

Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes

揭示罕见乳腺癌亚型的复杂性并把握其带来的机遇

Pareja, Fresia; Bhargava, Rohit; Borges, Virginia F; Brogi, Edi; Canas Marques, Rita; Cardoso, Fatima; Desmedt, Christine; Harigopal, Malini; Lakhani, Sunil R; Lee, Adrian; Leone, Jose Pablo; Linden, Hannah; Lord, Christopher J; Marchio, Caterina; Merajver, Sofia D; Rakha, Emad; Reis-Filho, Jorge S; Richardson, Andrea; Sawyer, Elinor; Schedin, Pepper; Schwartz, Christopher J; Tutt, Andrew; Ueno, Naoto T; Vincent-Salomon, Anne; Weigelt, Britta; Wen, Y Hannah; Schnitt, Stuart J; Oesterreich, Steffi

Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma.

依次抑制 ATR 和 PARP 可克服胰腺导管腺癌获得的 DNA 损伤剂耐药性

Herbert Katharine J, Upstill-Goddard Rosie, Dreyer Stephan B, Rebus Selma, Pilarsky Christian, Debabrata Mukhopadhyay, Lord Christopher J, Biankin Andrew V, Froeling Fieke E M, Chang David K